News for Armata Pharmaceuticals Inc. (ARMP)

Revenue: $1.2 million for Q4 2024, falling short of the estimated $1.56 million.Net Income: Achieved net income of $2.6 million for Q4 2024, a significant impr

PR NewswireLOS ANGELES, March 20, 2025 LOS ANGELES, March 20, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Com

PR NewswireLOS ANGELES, March 12, 2025 Proceeds to be used to continue to advance development of Armata's phage product candidates LOS ANGELES, March 12, 2

PR NewswireLOS ANGELES, March 11, 2025 LOS ANGELES, March 11, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Com

Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 46.43% and 230.33%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium

Revenue: Reported grant revenue of $1.0 million for Q1 2024, which is below the estimated revenue of $1.10 million.Net Loss: Recorded a net loss of $25.02 mill

The biotech industry is poised for robust growth due to increasing demand for personalized treatments, rising prevalence of chronic diseases, heightened investments in R&D, and advancements in technology. Therefore, investors...

Armata Pharmaceuticals Inc (ARMP) announced a Q3 2023 loss from operations of $(10.3) million, widening from $(8.6) million in Q3 2022.Grant revenue for Q3 202

Innoviva, Inc. is a biopharma company leveraging royalty revenues from GSK plc. INVA stock has had a rollercoaster ride, is it a buy now? Click here for my take.

/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics...

Increasing prevalence of antibiotic-resistant bacteria is one of the major factors driving market revenue growth ...

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific...

The following are some of the stocks making big moves in Monday's pre-market trading (as of 07.35 A.M. ET)..

The following are some of the stocks making big moves in Monday's pre-market trading (as of 07.35 A.M. ET)..

Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sleep apnea.

Read Analysts’ Updated EPS Estimates for May 18th (AAWH, AB, ADSE, AER, AIN, AMBP, ANIX, AOMR, AOWDF, ARMP) at ETF Daily News

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Insiders have been taking advantag...